Last edition
News about "AbbVie"
Takeda Becomes a BaseLaunch Partner
BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.
AbbVie | 19/12/2025 | By News Bureau
AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma
AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.
AbbVie | 19/11/2025 | By Dineshwori
Indian Pharmaceutical Alliance Welcomes New Leadership
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, and Vice President, Indian Pharmaceutical Alliance (IPA), has been appointed President of the alliance, while Glenn Saldanha, Chairman and Managing Director, Glenmark, will serve as the new Vice President.
AbbVie | 04/10/2025 | By Dineshwori | 139
AbbVie has begun a USD 70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, and broken ground on a new North Chicago Active Pharmaceutical Ingredient (API) manufacturing facility.
AbbVie | 01/10/2025 | By Dineshwori | 174
Ichnos Glenmark Innovation Secures USD 700M Upfront in AbbVie Licensing Deal for ISB 2001
Ichnos Glenmark Innovation (IGI) has received an upfront payment of USD 700 million from AbbVie under the terms of their recently announced global licensing agreement for IGI’s lead investigational asset, ISB 2001.
AbbVie | 09/09/2025 | By Dineshwori | 174
AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal
AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.
AbbVie | 26/08/2025 | By Mrinmoy Dey | 123
AbbVie Announces Completion of Acquisition of Capstan Therapeutics
AbbVie has completed its acquisition of Capstan Therapeutics, bringing onboard Capstan’s tLNP platform and lead asset CPTX2309 to advance next-generation in vivo CAR-T therapies for autoimmune diseases.
AbbVie | 20/08/2025 | By Mrinmoy Dey | 177
AbbVie to Invest USD 195 Million to Expand API Manufacturing in US
AbbVie will invest USD 195 million to expand active pharmaceutical ingredient manufacturing at its North Chicago plant, strengthening US production capacity for current and next-generation medicines.
AbbVie | 13/08/2025 | By Mrinmoy Dey
Glenmark's IGI Signs Licensing Deal with AbbVie for Investigational Cancer Therapy
AbbVie to lead global development, manufacturing and commercialisation of Ichnos Glenmark Innovation’s (IGI) investigational cancer therapy ISB 2001 in North America, Europe, Japan, and Greater China, while Glenmark will take these roles in emerging markets.
AbbVie | 11/07/2025 | By Dineshwori | 165
AbbVie and REGENXBIO Update on ABBV-RGX-314 Clinical Program
AbbVie and REGENXBIO will plan a Phase 3 clinical program. The clinical program will utilize the in-office SCS Microinjector® to deliver gene therapy to the suprachoroidal space of the eye.
AbbVie | 15/01/2025 | By Aishwarya | 356
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy